Sector
PharmaceuticalsOpen
₹1,689.9Prev. Close
₹1,687.3Turnover(Lac.)
₹15,274.11Day's High
₹1,739.9Day's Low
₹1,670.552 Week's High
₹1,868.852 Week's Low
₹560.2Book Value
₹171.32Face Value
₹5Mkt Cap (₹ Cr.)
28,123P/E
0EPS
0Divi. Yield
0WCK 6777 is the only once-a-day antibiotic in the global pipeline designated for outpatient parenteral antimicrobial therapy (OPAT).
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 77 | 72 | 72 | 55 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,719 | 1,681 | 2,140 | 1,551 |
Net Worth | 1,796 | 1,753 | 2,212 | 1,606 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 1,372 | 987 | 890.06 | 2,477.29 |
yoy growth (%) | 39 | 10.89 | -64.07 | 7.82 |
Raw materials | -476 | -416 | -313.29 | -975.36 |
As % of sales | 34.69 | 42.14 | 35.19 | 39.37 |
Employee costs | -261 | -293 | -325.46 | -506.44 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -184 | -481 | -483.68 | 103.92 |
Depreciation | -171 | -184 | -173.39 | -106.24 |
Tax paid | 44 | 231 | 158 | -35.26 |
Working capital | 197 | -66.03 | -165.93 | -147.06 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 39 | 10.89 | -64.07 | 7.82 |
Op profit growth | -260.86 | 3.65 | -141.23 | 122.91 |
EBIT growth | -131.67 | 6.63 | -196.34 | -4.86 |
Net profit growth | -123.6 | -356.57 | -436.61 | -49.92 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 3,012 | 2,798 | 2,651 | 3,230 | 2,708 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,012 | 2,798 | 2,651 | 3,230 | 2,708 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 62 | 83 | 122 | 20 | 1,476 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
H F Khorakiwala
Managing Director
Murtaza H Khorakiwala
Executive Director
Huzaifa H Khorakiwala
Independent Director
Tasneem Mehta
Independent Director
Vinesh Kumar Jairath
Non-Exec & Non-Independent Dir
Zahabiya Khorakiwala
Independent Director
Akhilesh Gupta
Independent Director
Amelia Fernandes
Company Sec. & Compli. Officer
Rashmi Mamtura
Independent Director
Ahmad Javed
D-4 MIDC,
Chikalthana,
Maharashtra - 431006
Tel: 91-240-6694444
Website: http://www.wockhardt.com
Email: investorrelations@wockhardt.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. The Company is Indias leadi...
Read More
Reports by Wockhardt Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.